Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00781560 |
This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the percentage of hyperlipidemia patients who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) following 8-week treatment by Crestor® 5mg or 10mg
Condition |
---|
Hyperlipidemia |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | A Cross-Sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks |
Estimated Enrollment: | 2400 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | December 2009 |
Groups/Cohorts |
---|
1
patients being diagnosed as dyslipidemia but not receiving Crestor®
|
2
hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients who has been diagnosed as hypercholesterolemia and decided by physician to use Crestor® 5mg or 10mg or other regimens (TLC or other lipid-lowering agents)
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca China Clinical Study Information | 0086 21 5256 4555 | tristin.zhao@astrazeneca.com |
China | |
Research Site | |
Shanghai, China | |
Research Site | |
Beijing, China | |
China, Henan | |
Research Site | |
ZhengZhou, Henan, China | |
China, Hubei | |
Research Site | |
Wuhan, Hubei, China | |
China, Jiangsu | |
Research Site | |
Nanjing, Jiangsu, China | |
China, Liaoning | |
Research Site | |
Shenyang, Liaoning, China | |
China, Shandong | |
Research Site | |
Qingdao, Shandong, China | |
China, Shanxi | |
Research Site | |
Xi'an, Shanxi, China | |
China, Zhejiang | |
Research Site | |
Hang Zhou, Zhejiang, China | |
Research Site | |
Wenzhou, Zhejiang, China |
Study Director: | Karen Atkin | Astrazeneca China R&D |
Principal Investigator: | Zhu Junren | Zhongshan Hospital Fudan University |
Responsible Party: | AstraZeneca Pharmaceuticals ( Karen Atkin/ VP. China R&D ) |
Study ID Numbers: | NIS-CCN-CRE-2008/1 |
Study First Received: | October 28, 2008 |
Last Updated: | October 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00781560 |
Health Authority: | China: State Food and Drug Administration |
Hyperlipidemia Chinese National Adult Lipid Treatment Guideline (2007) Crestor® |
Rosuvastatin Metabolic Diseases Hyperlipidemias |
Metabolic disorder Dyslipidemias Lipid Metabolism Disorders |